Project Grant HT94252310600
Award Date
9/1/23
Completion Date
8/31/25
Dollars Obligated
$599K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Torrance, CA 90503, USA
Similar Awards
The Defense Health Agency awarded a $899,999 Project Grant to Wake Forest University Health Sciences under the Military Medical Research and Development program (CFDA 12.420) to develop a novel point-of-care assay for monitoring rejection and immunosuppression in vascularized composite allotransplantation (VCA) recipients. The project aims to transform healthcare for service members and the public through innovative biomedical research focused on medical solutions for the battlefield. The...
The Defense Health Agency awarded a $499,998.00 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "Identifying Biomarkers of Human VCA Rejection to Enable Noninvasive Diagnostic Testing." This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports biomedical research initiatives aimed at improving health outcomes for military service members, veterans, and the broader public. The research project at Brigham &...
The U.S. Department of Defense's Defense Health Agency (DHA) awarded a $750,000 Project Grant to Stanford University to implement a spatial and single-cell multiplexed platform for the development of targeted therapies for vascularized composite allotransplantation. The funding is provided through the Military Medical Research and Development (CFDA 12.420) federal grant program, which supports advanced biomedical research to transform healthcare for military service members and the broader...
The Defense Health Agency awarded a $410,000 Project Grant titled "Localized and Inflammation-Responsive Immunotherapy of VCA Rejection" to The Geneva Foundation, a 501(c)3 non-profit organization that supports medical research and education for the U.S. military. This grant is part of the "Military Medical Research and Development" program (CFDA 12.420), which funds basic, applied, and advanced biomedical research to transform healthcare for Service Members and the public...
This $653,317 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the development of a novel graft-localized drug delivery platform at Wake Forest University Health Sciences (WFUHS). The funding will be used to conduct research aimed at attenuating innate inflammation and optimizing immunosuppression in vascularized composite allotransplantation over a 2-year period from September 2024 to September 2026. WFUHS, a leading...
The Johns Hopkins University received a $722,589.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on localized and inflammation-responsive immunotherapy of vascular composite allograft (VCA) rejection. The 3-year project, which commenced on July 1, 2023 and is slated for completion by June 30, 2026, aims to transform healthcare for service members and the American public by investigating innovative...
The University of Massachusetts Medical School will deliver the Active Rejection Micro-Patch Surveillance (ARMS) System for Vascularized Composite Allografts under a $280,000 cooperative agreement awarded by the Defense Health Agency on September 30, 2022. The three-year award will support the development of a monitoring system to detect early signs of rejection in vascularized tissue transplants through the Military Medical Research and Development program (CFDA 12.420). This program aims to...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $818,337 to Vascular Perfusion Solutions Inc. to conduct research on "Extended Limb Stasis in the Encore Tissue Preservation Device". The award period runs from August 15, 2025 to August 14, 2027. The research aims to transform healthcare for military service members, veterans, and the broader public through innovative biomedical...
This $483,548.00 Project Grant was awarded on August 1, 2024 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports "SINGLE-CELL STUDIES OF IMMUNE-MEDIATED INJURY AND IMMUNOREGULATION IN HUMAN VCA REJECTION" at Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in Boston, Massachusetts. The research funded by this grant aims to advance the understanding of...
This $1,016,449.00 Project Grant award was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports single-cell studies of immune-mediated injury and immunoregulation in human vascular composite allograft (VCA) rejection, with a performance period from August 1, 2024 to July 31, 2027. The award was granted to Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in...